Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis.
PPARγ activators inhibit cancer cell growth. However the role of these agents in progression/metastasis is not well-defined. Using an orthotopic model of lung cancer, we showed that pioglitazone accelerated progression/metastasis through affects on macrophages. This suggests that potential therapeutic agents may have opposing effects on cancer in different cells.
SourceOncoimmunology 1:3 2012 May 1 pg 403-404
Pub Type(s)JOURNAL ARTICLE